UB

Upstream Bio, Inc.

UPB·NASDAQ

$20.97

-5.9%
HealthcareBiotechnology

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$1.13B
EPS-0.7400
P/E Ratio-3.69
Earnings Date11/06/2025

upb

Cost of Revenue

Last Annual Value

89.00K

3-Year CAGR

133%

5-Year CAGR

66%

10-Year CAGR

29%

UB

Upstream Bio, Inc. Competitors Analysis of Cost of Revenue

UPB · NASDAQ
CompanyCost of Revenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
89.00K
14.0%N/AN/A 
0.00
N/AN/AN/A
140.00K
-88.3%N/AN/A
7.32M
N/AN/AN/A
3.56M
N/AN/AN/A
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
0.00
N/AN/AN/A
56.00K
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
22.60M
413.4%112.5%N/A
UB

Upstream Bio, Inc. Fair Value Envelope

UPB · NASDAQ

Our analysis suggests that UPB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20.97, this represents a potential HIDDEN relative to our calculated worth for Upstream Bio, Inc..

Intrinsic Value
Current Price: $20.97